Search PubMed⌕ Search

PubMed · 11346840

A simple institutional educational intervention to decrease use of selected expensive medications.

Abstract

OBJECTIVE: To determine whether a simple educational intervention can influence use of prescription medications at an institution. DESIGN: Cost-effectiveness analysis of prescribing behavior before and after an educational intervention. SETTING: A large, urban, free-standing academic rehabilitation hospital. PARTICIPANTS: Physicians, residents, and physician extenders. INTERVENTIONS: The hospital's pharmacy department provided simple written educational material about cost differences of various prescription medications to attending and resident physicians, nurse leaders, and case managers. Telephoned reminders were given when targeted medications were prescribed. MAIN OUTCOME MEASURES: Total prescription medication use was recorded monthly for 12 months before and after the intervention. Pharmaceuticals monitored were subcutaneously administered anticoagulants, histamine type 2 (H2) blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs). RESULTS: A 32% decrease in use of the more costly anticoagulant and a 20% increase in use of the less costly anticoagulant (p <.0001), representing an estimated annual savings of nearly $66,000. Use of more costly H2 antagonist decreased 50% and use of less costly H2 antagonist increased 128% (p <.0001). With written intervention only, use of more costly NSAIDs declined 28%, whereas use of less costly NSAIDs increased 58% (p <.0020). CONCLUSION: Providing physicians with simple pharmaceutical cost information and telephone reminders decreased the use of targeted more costly medications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E J Roth, C T Plastaras, M S Mullin, J Fillmore, M L Moses. 2001. A simple institutional educational intervention to decrease use of selected expensive medications.. https://doi.org/10.1053/apmr.2001.22624

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Development and validation of a capillary electrophoresis method for ximelagatran assay and related substance determination in drug substance and tablets.

The advantages of simplicity, selectivity, versatility and ease of use of free solution capillary electrophoresis (CE) present an orthogonal and complementary separation technique to the established methods of liquid chromatography (LC) for pharmaceutical analysis. This work presents the development and performance of a suitable CE method for ximelagatran (formerly H 376/95) assay and related substance determination in both drug substance and tablets. The method employed was a low pH phosphate buffer, to which acetonitrile and hydroxypropyl-beta-cyclodextrin were added, in order to facilitate the separation of ximelagatran and its related substances. An applied field of 350 V/cm was used and all compounds were resolved in approximately 20 min. Benzamidine hydrochloride was used as an internal standard in quantification. The data indicate that the performance of the validated method offers equivalent and complementary information, in terms of selectivity, sensitivity, accuracy, linearity and precision, to that of an established gradient LC method employed for similar purposes. Robustness of the method was investigated by experimental design and evaluated using multivariate calculations.

Anticoagulants↗

Coagulation inhibitors in the treatment of sepsis.

Despite advances in supportive care, sepsis and septic shock continue to be major causes of morbidity and mortality in critically ill patients. The lack of efficacy of anti-inflammatory drugs in patients with sepsis has shifted interest toward developing alternative treatments. The observation that clotting system activation may in part underlie the physiological derangements of sepsis has resulted in efforts to target the clotting cascade as a therapeutic strategy. Anticoagulants have been shown to ameliorate physiological derangements and improve survival in animal sepsis models. Three agents have undergone extensive study in humans: recombinant human activated protein C (rhAPC, drotrecogin-alpha), antithrombin III (ATIII) and tissue factor pathway inhibitor (TFPI). While a recent Phase III study of rhAPC suggests a survival benefit in patients with sepsis, major concerns about this trial include the manner in which the study was conducted, the potential toxicity of rhAPC and the questionable efficacy of this agent in patients with low mortality risk. Further clinical testing of rhAPC appears to be necessary to better define the target population most appropriate for its use. In contrast, a large Phase III study of high dose ATIII in patients with sepsis failed to show a treatment benefit with this agent. Finally, while TFPI has undergone extensive preclinical and Phase II testing, the results of Phase III studies have not been published. In summary, while coagulation inhibitors may ultimately have a therapeutic role in selected subgroups of patients with sepsis, the efficacy and safety of this class of agents remain to be proven.

Anticoagulants↗